OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gomella Discusses Role of BRCA1/2 in Prostate Cancer

March 22nd 2019

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of BRCA1/2 in patients with prostate cancer.

Dr. Davids on Frontline Challenges in CLL

March 21st 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Landen Discusses p53 Mutations in Ovarian Cancer

March 20th 2019

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the role of p53 mutations in patients with ovarian cancer.

Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast Cancer

March 20th 2019

Stephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.

Dr. Cho on Promising Combinations in Multiple Myeloma

March 20th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Dr. Rao on Treatment De-Escalation in HR+/HER2- Breast Cancer

March 20th 2019

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

Dr. Patel on Emerging Therapeutic Strategies in MCL

March 20th 2019

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Dr. Kris on Personalizing Therapy in Lung Cancer

March 20th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses personalizing therapy in the treatment of patients with lung cancer.

Dr. Shum Discusses Dacomitinib in EGFR+ NSCLC

March 20th 2019

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses the use of dacomitinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Decker on Distinct Roles of Radiation in Lung Cancer

March 20th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses traditional roles of radiation therapy in the treatment of patients with lung cancer.

Dr. George on Dosing TKIs in RCC

March 20th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).

Dr. Holstein on BiTEs in Multiple Myeloma

March 19th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

Dr. Nimer on CAR T-Cell Therapy in Hematologic Malignancies

March 19th 2019

Stephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

March 19th 2019

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Dr. Lossos on Treatment Approaches in MCL

March 19th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses treatment approaches for patients with mantle cell lymphoma (MCL).

Dr. Grivas on Immunotherapy in Platinum-Refractory Metastatic Bladder Cancer

March 19th 2019

Petros Grivas, MD, PhD, director of Genitourinary Cancers Program and associate professor of Oncology, University of Washington, medical oncologist, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with metastatic platinum-refractory bladder cancer.

Dr. Vallieres on Postoperative QoL in Patients With Lung Cancer

March 19th 2019

Eric Vallieres, MD, medical director, Division of Thoracic Oncology, Swedish Cancer Institute, discusses postoperative quality of life in patients with lung cancer.

Dr. Shuch on Role of Cytoreductive Nephrectomy in RCC

March 19th 2019

Brian M. Shuch, MD, director of the Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discussed the role of cytoreductive nephrectomy in renal cell carcinoma.

Dr. Jahanzeb on Immunotherapy in Oncogene-Driven NSCLC

March 19th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.

Dr. Powles on the Results of the KEYNOTE-426 Trial in mRCC

March 15th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).